Hyperthermia enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human cancer cells

References

• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–12690
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813–820
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165–1170
   PubMed Web of Science ®Google Scholar
• Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, et al. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 1997; 7: 1003–1006
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818
   PubMed Web of Science ®Google Scholar
• Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–113
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818–821
   PubMed Web of Science ®Google Scholar
• Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386–5397
   PubMed Web of Science ®Google Scholar
• Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099–18104
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255–260
   PubMed Web of Science ®Google Scholar
• Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997; 277: 768
   PubMed Web of Science ®Google Scholar
• Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734–741
   PubMed Web of Science ®Google Scholar
• Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833–2840
   PubMed Web of Science ®Google Scholar
• Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411–415
   PubMed Web of Science ®Google Scholar
• Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96: 3900–3906
   PubMed Web of Science ®Google Scholar
• Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 1999; 274: 1646–1656
   PubMed Web of Science ®Google Scholar
• Tschopp J, Martinon F, Hofmann K. Apoptosis: silencing the death receptors. Curr Biol 1999; 9: R381–R384
   Web of Science ®Google Scholar
• Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, Francke U, Reed JC, Kinoshita S, Nolan GP. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 1998; 8: 461–471
   PubMed Web of Science ®Google Scholar
• Kothny-Wilkes G, Kulms D, Luger TA, Kubin M, Schwarz T. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand- and CD95-induced apoptosis but not from ultraviolet radiation-induced apoptosis. J Biol Chem 1999; 274: 28916–28921
   PubMedGoogle Scholar
• Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev 1999; 13: 239–252
   PubMed Web of Science ®Google Scholar
• Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315–5320
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med 1999; 5: 157–163
   PubMed Web of Science ®Google Scholar
• French LE, Tschopp J. The TRAIL to selective tumor death. Nature Med 1999; 5: 146–147
   PubMed Web of Science ®Google Scholar
• Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 2003; 89: 206–214
   PubMedGoogle Scholar
• Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 2003; 63: 5118–5125
   PubMed Web of Science ®Google Scholar
• Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847–853
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, Kim TH, Billiar TR, Song YK. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 2001; 20: 1476–1485
   PubMed Web of Science ®Google Scholar
• Fulda S, Jeremias I, Debatin KM. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004; 23: 7611–7620
   PubMed Web of Science ®Google Scholar
• Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97: 1754–1759
   PubMed Web of Science ®Google Scholar
• Park SY, Billiar TR, Seol DW. IFN-gamma inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-gamma-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Comm 2002; 291: 233–236
   PubMedGoogle Scholar
• Nyormoi O, Mills L, Bar-Eli M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Diff 2003; 10: 558–569
   PubMed Web of Science ®Google Scholar
• Lee YJ, Song JJ, Kim JH, Kim HR, Song YK. Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway. Exp Cell Res 2004; 293: 129–143
   PubMed Web of Science ®Google Scholar
• Nam SY, Amoscato AA, Lee YJ. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 2002; 21: 337–346
   PubMed Web of Science ®Google Scholar
• Lee YJ, Froelich CJ, Fujita N, Tsuruo T, Kim JH. Reconstitution of caspase-3 confers low glucose-enhanced tumor necrosis factor-related apoptosis-inducing ligand cytotoxicity and Akt cleavage. Clin Cancer Res 2004; 10: 1894–1900
   PubMedGoogle Scholar
• Lee YJ, Moon MS, Kwon SJ, Rhee JG. Hypoxia and low glucose differentially augments TRAIL-induced apoptotic death. Mol Cell Biochem 2005; 270: 89–97
   PubMed Web of Science ®Google Scholar
• Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA, Kapp DS. Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 1988; 11: 368–380
   PubMed Web of Science ®Google Scholar
• Riehemann K, Schmitt O, Ehlers EM. The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo. Ann Anat 2005; 187: 215–223
   PubMed Web of Science ®Google Scholar
• Ohguri T, Imada H, Kato F, Yahara K, Morioka T, Nakano K, Korogi Y. Radiotherapy with 8 MHz radiofrequency-capacitive regional hyperthermia for pain relief of unresectable and recurrent colorectal cancer. Int J Hyperthermia 2006; 22: 1–14
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomized trial, Dutch Deep Hyperthermia Group. Lancet 2000; 356: 771–772
   PubMedGoogle Scholar
• Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomize trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005; 23: 3079–3085
   PubMed Web of Science ®Google Scholar
• Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, Denecke H, Berger H, Peter K, Wilmanns W. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: A phase II study. J Clin Oncol 1990; 8: 1818–1829
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, Hiddemann W, Issels RD. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002; 20: 3156–3164
   PubMed Web of Science ®Google Scholar
• Kapp DS, Fressenden P, Samulski TV, Bagshaw MA, Cox RS, Lee ER, Lohrbach AW, Meyer JL, Prionas SD. Stanford University Institutional report. Phase I evalulation of hyperthermia equipment for hyperthermic treatment of cancer. Int J Hyperthermia 1988; 4: 75–116
   PubMed Web of Science ®Google Scholar
• Sapozink MD, Gibbs FA, Gibbs P, Stewart JR. Phase I evaluation of hyperthermia equipment: University of Utah Institutional report. Int J Hyperthermia 1988; 4: 117–132
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–790
   PubMed Web of Science ®Google Scholar
• Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS. Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 1998; 58: 4940–4946
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006; 84: 87–98
   PubMed Web of Science ®Google Scholar
• Ryu S, Brown SL, Kim SH, Khil MS, Kim JH. Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 1996; 34: 133–138
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Miao J, Ng CE. Cisplatin and mild hyperthermia in radiosensitization to low dose rate irradiation in human ovarian carcinoma cells. Anticancer Res 1997; 17: 3469–3472
   PubMedGoogle Scholar
• Atallah D, Marsaud V, Radanyi C, Kornprobst M, Rouzier R, Elias D, Renoir JM. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia 2004; 20: 405–419
   PubMed Web of Science ®Google Scholar
• Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005; 21: 761–767
   PubMed Web of Science ®Google Scholar
• Srinivasan JM, Fajardo LF, Hahn GM. Mechanism of antitumor activity of tumor necrosis factor alpha with hyperthermia in a tumor necrosis factor alpha-resistant tumor. J Natl Cancer Inst 1990; 82: 1904–1910
   PubMedGoogle Scholar
• Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, Tomasovic SP. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 1992; 52: 5271–5277
   PubMedGoogle Scholar
• Lee YJ, Hou Z, Curetty L, Cho JM, Corry PM. Synergistic effects of cytokine and hyperthermia on cytotoxicity in HT-29 cells are not mediated by alteration of induced protein levels. J Cell Physiol 1993; 155: 27–35
   PubMed Web of Science ®Google Scholar
• Ozoren N, El-Deiry W. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Exp Cell Res 2002; 281: 175–181
   Google Scholar
• Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nature Cell Biol 2000; 2: 469–475
   PubMed Web of Science ®Google Scholar
• Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 2000; 2: 476–483
   PubMed Web of Science ®Google Scholar
• Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V, Weichselbaum R, Nalin C, Alnemri ES, Kufe D, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000; 19: 4310–4322
   PubMed Web of Science ®Google Scholar
• Ran R, Zhou G, Lu A, Zhang L, Tang Y, Rigby AC, Sharp FR. Hsp70 mutant proteins modulate additional apoptotic pathways and improve cell survival. Cell Stress Chap 2004; 9: 229–242
   PubMed Web of Science ®Google Scholar
• Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jaattela M, Penninger JM, Garrido C, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001; 3: 839–843
   PubMed Web of Science ®Google Scholar
• Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ, Jr, el-Deiry WS. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58: 1593–1598
   PubMed Web of Science ®Google Scholar
• Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 1998; 273: 7770–7775
   PubMed Web of Science ®Google Scholar
• Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129–1132
   PubMed Web of Science ®Google Scholar
• Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ, Fritz LC. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem 1997; 272: 30299–30305
   PubMed Web of Science ®Google Scholar